Roche gets pri­or­i­ty re­view for Hem­li­bra's sec­ond in­di­ca­tion; Ora­sis gets $13M B round for pres­by­opia eye drop

→ Roche $RHH­BY is now one step clos­er to re­al­iz­ing its block­buster am­bi­tions for Hem­li­bra, se­cur­ing a pri­or­i­ty re­view for a sec­ond, huge­ly im­por­tant in­di­ca­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER